TOBI™ Podhaler™ 112 mg inhaled twice daily
Idiopathic Pulmonary Fibrosis
Clinical trials
1
Developer
Dartmouth-Hitchcock Medical Center
Overview
TOBI™ Podhaler™ 112 mg inhaled twice daily is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis. It appears in 1 tracked IPF clinical trial.
TOBI™ Podhaler™ 112 mg inhaled twice daily clinical trials
Explore related
Medical disclaimer. This page summarizes research about TOBI™ Podhaler™ 112 mg inhaled twice daily for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.